AAO 2023: OcuTerra's CEO shares update on diabetic retinopathy treatment study
November 3rd 2023Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.
Read More
FDA grants Toku Breakthrough Device status for its cardiovascular risk AI platform
November 2nd 2023The company’s AI CLAIR technology platform has received FDA breakthrough device status, and if cleared by the FDA will deliver real-time cardiovascular disease risk assessments through routine eye exams.
Read More
Clearside Biomedical completes recruitment in ODYSSEY Phase 2b clinical trial of CLS-AX in wet AMD
November 1st 2023The clinical trial will evaluate the safety and efficacy of CLS-AX (axitinib injectable suspension), a tyrosine kinase inhibitor. According to the company, topline data is expected during the third quarter of 2024.
Read More
Study: “Pseudo cell” formulation targets vitreoretinal disease
October 28th 2023Researchers have delved into the possibility of cell-based therapy in ophthalmology. By targeting vitreoretinal diseases, they are tackling a range of vision-threatening disorders which often result in severe irreversible vision loss.
Read More
FDA approves faricimab-svoa for the treatment of retinal vein occlusion
October 27th 2023According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.
Read More
Visgenx issued patent for compositions of ELOVL2 gene therapy
October 26th 2023The issuance provides patent protection in the U.S. for therapeutics incorporating the optimized ELOVL2 transgene until 2041. The patent is being prosecuted in the European Union and other countries around the globe. The company said the patent adds value to its lead program in dry AMD.
Read More
Study: Collaboration across disciplines ensuring fairness of AI in healthcare
October 24th 2023According to a study by a team of scientists led by Duke-NUS Medical School, pursuing fair AI for healthcare requires cross-disciplinary collaboration to translate methods into real-world benefits.
Read More
Conflict in Israel could have dire impact on ophthalmic care in country
October 17th 2023In the wake of the October 7 surprise attack by Hamas, Israel finds itself thrust into war, and ophthalmologists are working to provide the best care they can under the conditions they find themselves in.
Read More
ICTER researchers achieve potential breakthrough in the diagnosis of eye diseases
October 13th 2023Researchers at the Warsaw, Poland-based International Center for Translational Eye Research decided to change that by introducing a new imaging method derived from optical coherence tomography. This led to the creation of even more advanced spatio-temporal optical coherence tomography.
Read More
FDA grants 510(k) clearance to Altris IMS platform
October 4th 2023Altris also has advanced AI models to enable vendor-neutral retina layers segmentation as well as detection and visualization of more than 70 retina conditions such as dry and wet age-related macular degeneration, geographic atrophy, diabetic retinopathy, diabetic macular edema and central retinal vein occlusion.
Read More